Literature DB >> 26667447

Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease.

Phillip J Ngu1,2, Michelle Butler1,2, Alan Pham3, Stuart K Roberts4, Andrew J Taylor5,6.   

Abstract

Chronic cardiac dysfunction in patients with chronic liver disease (CLD) in the absence of alcohol consumption or other cardiac disease is well described. Whilst functional and morphological features of this condition remain unclear, diastolic dysfunction has been implicated by echocardiography. We aimed to evaluate myocardial structure, function and tissue composition with cardiac magnetic resonance (CMR) imaging in patients with hepatitis C and histological evidence of liver disease on biopsy. Contrast-enhanced CMR imaging for morphological, functional and tissue characterization was performed on 16 patients with CLD and 21 healthy controls. Cardiac structure and function was assessed with standard cine imaging, with Late Gadolinium Enhancement (LGE) and myocardial T1 mapping (pre- and post-contrast) performed to evaluate regional and diffuse myocardial fibrosis respectively. Compared to controls, patients with CLD demonstrated lower left ventricular end-diastolic volume (LVEDV) (138 ± 36 vs. 167 ± 44 mL, p < 0.05), reduced stroke volume (88 ± 20 vs. 109 ± 29 mL, p = 0.016), lower post-contrast myocardial T1 time and higher Partition Coefficient consistent with diffuse myocardial fibrosis (466 ± 78 vs. 545 ± 134 ms and 0.247 ± 0.110 vs. 0.123 ± 0.057 %, p < 0.05 for both). There were no differences in other cardiac parameters including left ventricular mass and ejection fraction (p = NS for all comparisons). No patients in either group had evidence of LGE. Compared to controls, patients with hepatitis C and histological evidence liver involvement have lower LVEDV, SV and increased diffuse myocardial fibrosis, all of which are associated with diastolic dysfunction. LVEF and LV mass were preserved. This may explain in part previous functional observations made by echocardiography.

Entities:  

Keywords:  Diastolic dysfunction; Hepatitis C; Liver disease; Myocardial fibrosis; T1 time

Mesh:

Substances:

Year:  2015        PMID: 26667447     DOI: 10.1007/s10554-015-0824-6

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  43 in total

Review 1.  Cirrhotic cardiomyopathy.

Authors:  Søren Møller; Jens H Henriksen
Journal:  J Hepatol       Date:  2010-03-31       Impact factor: 25.083

Review 2.  A perspective on cirrhotic cardiomyopathy.

Authors:  T Timoh; M A Protano; G Wagman; M Bloom; T J Vittorio
Journal:  Transplant Proc       Date:  2011-06       Impact factor: 1.066

3.  Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt.

Authors:  Massimo Cazzaniga; Francesco Salerno; Giovanni Pagnozzi; Elena Dionigi; Stefania Visentin; Ilaria Cirello; Daniele Meregaglia; Antonio Nicolini
Journal:  Gut       Date:  2006-11-29       Impact factor: 23.059

4.  T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison.

Authors:  Neville Gai; Evrim B Turkbey; Saman Nazarian; Rob J van der Geest; Chia-Ying Liu; João A C Lima; David A Bluemke
Journal:  Magn Reson Med       Date:  2010-12-16       Impact factor: 4.668

5.  Prediction of cardiac complications after liver transplantation.

Authors:  Tamer R Fouad; Wael M Abdel-Razek; Kelly W Burak; Vincent G Bain; Samuel S Lee
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

Review 6.  Hepatitis C virus (HCV) infection: a systemic disease.

Authors:  Antonio Craxì; Giacomo Laffi; Anna Linda Zignego
Journal:  Mol Aspects Med       Date:  2007-11-21

7.  Role of left ventricular stiffness in heart failure with normal ejection fraction.

Authors:  Dirk Westermann; Mario Kasner; Paul Steendijk; Frank Spillmann; Alexander Riad; Kerstin Weitmann; Wolfgang Hoffmann; Wolfgang Poller; Matthias Pauschinger; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Circulation       Date:  2008-04-14       Impact factor: 29.690

Review 8.  Myocardial T1 mapping: modalities and clinical applications.

Authors:  Christine L Jellis; Deborah H Kwon
Journal:  Cardiovasc Diagn Ther       Date:  2014-04

9.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.

Authors:  Leah Iles; Heinz Pfluger; Arintaya Phrommintikul; Joshi Cherayath; Pelin Aksit; Sandeep N Gupta; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

10.  Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials.

Authors:  Songtao Liu; Jing Han; Marcelo S Nacif; Jacquin Jones; Nadine Kawel; Peter Kellman; Christopher T Sibley; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2012-12-28       Impact factor: 5.364

View more
  3 in total

1.  Cardiovascular risk assessment by electrocardiographic Holter monitoring in patients with chronic hepatitis C.

Authors:  Adam R Poliwczak; Jolanta Białkowska; Joanna Woźny; Marzena Koziróg; Agnieszka Bała; Maciej Jabłkowski
Journal:  Arch Med Sci       Date:  2020-07-15       Impact factor: 3.318

Review 2.  Hepatitis C virus and cardiovascular: A review.

Authors:  Salvatore Petta
Journal:  J Adv Res       Date:  2016-06-18       Impact factor: 10.479

3.  Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons.

Authors:  Kara W Chew; Chia-Ying Liu; Bharath Ambale-Venkatesh; Diana Liao; Tamara B Horwich; João A C Lima; David A Bluemke; J Paul Finn; Adeel A Butt; Judith S Currier
Journal:  J Int Med Res       Date:  2017-06-12       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.